Davita Inc vs Matson Inc — how do they compare? Davita Inc trades at $179.05 (market cap $11.29B), while Matson Inc trades at $225.53 (market cap $6.81B). The key difference: Davita Inc is the larger of the two by market cap, and Matson Inc pays a 0.67% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Matson Inc for 23 Days on average.
| DVA | MATX | |
|---|---|---|
Market Cap | $11.29B | $6.81B |
Volume | 582,204 | 255,080 |
Sector | Health | Industrials |
52-Week High | $240.96 | $238.60 |
52-Week Low | $103.87 | $88.05 |
Typical Hold Time | 114 Days | 23 Days |
Enterprise Value | $24.01B | $7.41B |
Dividend Yield | — | 0.67% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.02, up 1.26% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 6.05% net margins and 635% ROE. Recent partnerships with Humana expand value-based kidney care services, while institutional investors like BlackRock added significant positions. Revenue growth remains steady at $13.6B annually with improving profitability trends.
DVA presents a mixed outlook with strong operational performance offset by technical weakness. The 43% upside to consensus price target of $235.67 offers potential, but high debt levels and regulatory risks require monitoring. Recent earnings momentum and expanding Medicare partnerships support long-term growth, though current technical indicators suggest near-term consolidation.
Matson (MATX) trades at $224.80, up 0.84% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong Q2 2026 earnings of $4.27 per share, beating estimates, and raised its full-year outlook. Revenue growth is steady, with 2026 revenue projected at $3.5 billion and net profit at $464 million, supported by a robust net income margin of 13.41%.
The outlook for MATX is positive, driven by earnings beats, cost controls, and institutional accumulation. Key risks include exposure to freight demand cycles and competitive pressures. Wall Street consensus is bullish, with 8 of 12 analysts rating it a Buy and an implied 27.33% upside potential, though investors should monitor macroeconomic trends affecting transportation stocks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →